Biotronik yesterday presented two-year data from a trial comparing Boston Scientific‘s (NYSE:BSX) Synergy biodegradable polymer everolimus-eluting stent, Biotronik’s Orsiro sirolimus-eluting stent and Medtronic‘s (NYSE:MDT) Resolute Integrity zotarolimus-eluting stent.
Results from the 3,514-patient trial showed no significant difference between the various stents regarding the rate of target vessel failure after two years. But analyses of one-year data found differences between the rates of target lesion revascularization and target lesion failure for patients treated with Orsiro compared to Resolute Integrity, according to Biotronik.
The study’s primary endpoint was a composite of cardiac death, target vessel-related myocardial infarction and target vessel revascularization at 12 months. Secondary endpoints included all-cause mortality, clinically-indicated target lesion revascularization and stent thrombosis.
After two years, the rate of target vessel failure for patients treated with Biotronik’s Orsiro device was 6.6%, compared to 6.8% for those treated with Boston Scientific’s Synergy stent and 8.3% for those treated with Medtronic’s Resolute Integrity device.
The rate of target lesion revascularization for patients treated with Orsiro was 0.6% compared to 1.5% for the Resolute Integrity group and 0.9% for the Synergy group after two years.
Investigators concluded that the use of Orsiro versus Resolute Integrity and Synergy may reduce the risk of repeat revascularization one year after the device is placed, although there was no significant difference between the three stents regarding the study’s primary endpoint.
“Long-term data will be of interest, given the landmark analyses provided a signal that the use of Orsiro might reduce the risk of repeat revascularization after the first year of follow-up,” principal investigator Dr. Marlies Kok said in prepared remarks.
Updated 5/25 to correct the rates of target vessel failure as reported by Biotronik.